Viatris Agreed to Acquire Pacira BioSciences
The pharmaceutical company announced a deal to purchase Pacira BioSciences for $1.65 billion.
Updated on Oct. 8, 2026 in Healthcare
Live Poll
Do you believe large-scale pharmaceutical company mergers generally benefit healthcare consumers?
Viatris has reached an agreement to acquire Pacira BioSciences, a firm specializing in non-opioid pain relief medications. The acquisition is valued at $1.65 billion.
Why it matters
Viatris aims to incorporate the Pacira portfolio into its existing global infrastructure to sustain long-term sales and extend product lifecycles. This strategy seeks to maximize value for the combined entity even after competitors enter the market.
Viatris finalized the acquisition agreement for $1.65 billion. This transaction focuses on the portfolio of non-opioid pain medicines currently sold by Pacira BioSciences.
The players
Viatris
Viatris is a global healthcare company formed through the combination of Mylan and Upjohn that focuses on providing access to medicine.
Pacira BioSciences
Pacira BioSciences is a provider of non-opioid pain management and regenerative health solutions for surgical settings.
The details
Viatris plans to leverage its extensive intellectual property expertise and global distribution network to expand the reach of the acquired non-opioid treatment line. The company intends to focus on maintaining sales momentum for these assets throughout their life cycle.
Timeline
October 8, 2026: Viatris announced the official acquisition agreement.
Market Landscape
This acquisition follows the industry trend of companies expanding portfolios to include non-opioid alternatives as public and regulatory pressure mounts against traditional pain medications. By absorbing Pacira BioSciences, Viatris strengthens its position in the specialized pain management sector against competitors.
Patients and healthcare providers may see shifts in the availability or distribution of non-opioid pain treatments as Viatris integrates the new portfolio. Pricing for these products remains subject to the company's future commercial strategy.
The takeaway
The deal signals a significant consolidation in the non-opioid treatment market as large firms seek to secure stable assets. Investors should watch how Viatris utilizes its global network to sustain the growth of these specialized medical products.
Further reading
For more information on trends in the pharmaceutical sector, visit the Healthcare section.
Live Poll
Do you believe large-scale pharmaceutical company mergers generally benefit healthcare consumers?
